Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

NCT04472767 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
HCC

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab
DRUG: Cabozantinib
PROCEDURE: Transarterial Chemoembolization

Sponsor

University of California, Irvine

Collaborators

[object Object]